Condition:   Childhood Cancer
Intervention:   Other: Needs Assessment Survey of Adult Childhood Cancer Survivors
Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2010

Condition:   Cardiomyopathy
Intervention:   Other: 12 Week Exercise Intervention
Sponsor:   St. Jude Children's Research Hospital
Recruiting - verified February 2010

Condition:   Ependymoma
Intervention:   Drug: Carboplatin
Sponsors:   Children's Memorial Hospital;   Brown University
Not yet recruiting - verified March 2010

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: gemtuzumab ozogamicin
Sponsor:   Fred Hutchinson Cancer Research Center
Not yet recruiting - verified March 2010

Condition:   Cardiovascular Disease
Interventions:   Other: Apple Juice/Grape Juice;   Other: Grape Juice/Apple Juice
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vinorelbine ditartrate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: allogeneic CMV/AdV-specific cytotoxic T lymphocytes;   Other: laboratory biomarker analysis
Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Condition:   Brain and Central Nervous System Tumors
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Genetic: DNA ploidy analysis;   Genetic: fluorescence in situ hybridization;   Genetic: microsatellite instability analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Methemoglobinemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
Interventions:   Drug: chemotherapy;   Drug: dapsone;   Other: medical chart review;   Procedure: assessment of therapy complications
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoblastic Leukemia, Acute, Childhood
Intervention:   Drug: Clofarabine incorporated into a 5-drug regimen
Sponsor:   Genzyme
Recruiting - verified October 2009

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm
Interventions:   Biological: trivalent influenza vaccine;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Cancer
Interventions:   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Cancer
Interventions:   Genetic: DNA analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: medical chart review;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: evaluation of cancer risk factors
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2009

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: MET tyrosine kinase inhibitor PF-02341066;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: obatoclax mesylate;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: pazopanib hydrochloride;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: Fludarabine Phosphate;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation (TBI);   Device: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
Sponsors:   Yale University;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Recruiting - verified August 2008

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Brain and Central Nervous System Tumors
Intervention:  
Sponsor:   St. Jude Children's Research Hospital
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: cryopreservation
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: DNA methylation analysis;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: cixutumumab;   Drug: temsirolimus;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: western blotting;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: thiotepa;   Drug: vincristine sulfate;   Drug: vorinostat;   Genetic: fluorescence in situ hybridization;   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Procedure: adjuvant therapy
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Fanconi Anemia;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified November 2009

Conditions:   Adrenocortical Carcinoma;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
Interventions:   Biological: cixutumumab;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: Hedgehog antagonist GDC-0449;   Genetic: gene expression analysis;   Genetic: in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified January 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Kidney Cancer;   Liver Cancer;   Lymphoma;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: carboplatin;   Drug: dasatinib;   Drug: etoposide phosphate;   Drug: ifosfamide;   Genetic: microarray analysis;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: natural killer cell therapy;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified August 2009

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Genetic: polymerase chain reaction;   Other: pharmacological study;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsor:   Blood and Marrow Transplant Group of Georgia
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Psychosocial Effects of Cancer and Its Treatment;   Sarcoma
Interventions:   Other: educational intervention;   Other: informational intervention;   Other: internet-based intervention;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Other: survey administration;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care
Sponsors:   Tufts Medical Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: cytomegalovirus IE-1-specific cytotoxic T lymphocytes;   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Biological: therapeutic allogeneic lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunological diagnostic method;   Other: laboratory biomarker analysis
Sponsors:   Milton S. Hershey Medical Center;   National Cancer Institute (NCI)
Recruiting - verified December 2008

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Other: educational intervention
Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Leukemia;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: Aurora A kinase inhibitor MLN8237;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pediatric Cancers
Interventions:   Behavioral: Focus Group - Parent/Caregiver;   Behavioral: Focus Group - Pediatric Patient
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: imatinib mesylate;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: confocal microscopy;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: biopsy
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: cilengitide
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: dactinomycin;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Lymphoma;   Lymphoproliferative Disorder;   Nonneoplastic Condition;   Small Intestine Cancer
Intervention:   Biological: TGF-beta-resistant LMP-specific cytotoxic T-lymphocytes
Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Head and Neck Cancer;   Lymphoma;   Lymphoproliferative Disorder;   Nonneoplastic Condition;   Small Intestine Cancer
Interventions:   Biological: allogeneic LMP1-/LMP2- specific cytotoxic T-lymphocytes;   Biological: autologous LMP1-/LMP2- specific cytotoxic T-lymphocytes
Sponsor:   Baylor College of Medicine
Recruiting - verified June 2009

Condition:   Leukemia
Interventions:   Drug: SC-PEG E. coli L-asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: etoposide phosphate;   Drug: idarubicin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Cancer;   Central Venous Catheters;   Deep Vein Thrombosis;   Catheter-related Infection;   Catheter-related Occlusion
Intervention:   Drug: Enoxaparin
Sponsor:   University of Texas Southwestern Medical Center
Recruiting - verified February 2009

Condition:   Cancer
Interventions:   Drug: montelukast sodium;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2008

Condition:   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Biological: aflibercept
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition
Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsor:   Baylor College of Medicine
Recruiting - verified June 2009

Condition:   Pediatric Cancers
Intervention:   Procedure: Carotid Ultrasound
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: rituximab;   Drug: clofarabine;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Conditions:   Pediatric Cancers;   Oncology
Intervention:  
Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI);   Children's Oncology Group;   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: immunological diagnostic method;   Procedure: adjuvant therapy
Sponsor:   Baylor College of Medicine
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Infection;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Lymphoma;   Lymphoproliferative Disorder;   Sarcoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure;   Other: immunologic technique;   Procedure: biopsy;   Procedure: study of high risk factors
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified August 2009

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Neuroblastoma;   Testicular Germ Cell Tumor;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: busulfan;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Leukemia
Intervention:   Drug: asparaginase-Erwinia
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Solid Tumors
Intervention:   Drug: Doxercalciferol
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
Sponsor:   Milton S. Hershey Medical Center
Recruiting - verified October 2007

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: beclomethasone dipropionate;   Drug: methotrexate;   Drug: tacrolimus;   Other: placebo
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Ototoxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: bevacizumab;   Drug: cediranib maleate;   Genetic: TdT-mediated dUTP nick end labeling assay;   Other: flow cytometry;   Other: fluorescent antibody technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: graft-versus-tumor induction therapy;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   Wake Forest University;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified July 2008

Conditions:   Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions:   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8
Sponsor:   Memorial Sloan-Kettering Cancer Center
Recruiting - verified July 2009

Condition:   Cancer
Interventions:   Other: counseling intervention;   Other: educational intervention;   Procedure: psychosocial assessment and care
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified December 2008

Conditions:   Cognitive/Functional Effects;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: cognitive assessment;   Procedure: diffusion tensor imaging;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Secondary Myelofibrosis
Interventions:   Biological: filgrastim;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   The Canadian Blood and Marrow Transplant Group;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Cancer
Intervention:   Drug: lithium carbonate
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Adults;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Sexual Dysfunction and Infertility;   Sexuality and Reproductive Issues;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: laboratory biomarker analysis;   Procedure: fertility assessment and management;   Procedure: management of therapy complications;   Procedure: ultrasound imaging
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis;   Small Intestine Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Secondary Myelofibrosis
Interventions:   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Graft Versus Host Disease;   Leukemia
Interventions:   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: methotrexate;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Neurotoxicity;   Peripheral Neuropathy;   Sarcoma
Interventions:   Dietary Supplement: glutamic acid;   Other: placebo
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI);   Children's Oncology Group
Recruiting - verified February 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Neurotoxicity;   Peripheral Neuropathy;   Sarcoma
Interventions:   Dietary Supplement: glutamine;   Other: placebo
Sponsor:   Herbert Irving Comprehensive Cancer Center
Recruiting - verified December 2008

Condition:   Cancer
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Drug: sorafenib tosylate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Biological: rituximab;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: ifosfamide;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Other: laboratory biomarker analysis;   Other: physiologic testing;   Procedure: biopsy;   Procedure: management of therapy complications
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2006

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Pulmonary Complications;   Sarcoma
Interventions:   Biological: etanercept;   Drug: methylprednisolone
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified October 2008

Condition:   Cancer
Interventions:   Procedure: music therapy;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   National Institute of Nursing Research (NINR)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: CD4+CD25+ regulatory T cells;   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   National Cancer Institute (NCI)
Recruiting - verified September 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Drug: clofarabine;   Drug: cyclophosphamide
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Unusual Cancers of Childhood
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: carmustine;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: cytarabine;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2007

Conditions:   Head and Neck Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Behavioral: compliance monitoring;   Drug: mercaptopurine;   Drug: methotrexate;   Other: study of socioeconomic and demographic variables
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsor:   James P. Wilmot Cancer Center
Recruiting - verified June 2007

Conditions:   Brain and Central Nervous System Tumors;   Chordoma;   Lymphoma;   Metastatic Cancer;   Von Hippel-Lindau Syndrome
Interventions:   Drug: mannitol;   Drug: melphalan
Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Radiation: radiation therapy
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: bone marrow ablation with stem cell support
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: Erlotinib hydrochloride
Sponsor:   St. Jude Children's Research Hospital
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: alemtuzumab;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Brain and Central Nervous System Tumors;   Carcinoma of Unknown Primary;   Leukemia;   Lymphoma;   Metastatic Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Drug: topotecan hydrochloride
Sponsors:   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2008

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: epratuzumab;   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2009

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma
Interventions:   Other: medical chart review;   Other: questionnaire administration;   Procedure: management of therapy complications
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Metastatic Cancer;   Neuroblastoma;   Sarcoma
Intervention:   Radiation: iodine I 131 monoclonal antibody 8H9
Sponsors:   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Ovarian Cancer;   Sarcoma;   Testicular Germ Cell Tumor
Intervention:   Biological: therapeutic allogeneic lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified December 2009

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: umbilical cord blood transplantation;   Drug: methylprednisolone
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis;   Genetic: gene expression analysis;   Other: immunologic technique;   Other: flow cytometry;   Genetic: polymerase chain reaction;   Genetic: cytogenetic analysis;   Other: staining method
Sponsor:   Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: genetic linkage analysis;   Genetic: microarray analysis;   Other: counseling intervention;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2007

Conditions:   Leukemia;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
Sponsor:   Medical College of Wisconsin
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsor:   Roswell Park Cancer Institute
Recruiting - verified June 2009

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2009

Conditions:   Growth Disorder;   Mental Retardation;   Multiple Abnormalies
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified March 2009